Published in J Neural Transm on January 01, 1976
Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain (2013) 2.09
Substantia nigra hyperechogenicity is a risk marker of Parkinson's disease: no. J Neural Transm (Vienna) (2010) 2.07
Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol (2010) 1.88
Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol (2005) 1.52
Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons. Proc Natl Acad Sci U S A (2012) 1.40
Axon degeneration in Parkinson's disease. Exp Neurol (2012) 1.40
Calcium homeostasis, selective vulnerability and Parkinson's disease. Trends Neurosci (2009) 1.34
Calcium, cellular aging, and selective neuronal vulnerability in Parkinson's disease. Cell Calcium (2010) 1.34
Phasic dopamine release in appetitive behaviors and drug addiction. Curr Drug Abuse Rev (2009) 1.30
The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease. Neuroscience (2011) 1.20
CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson's disease. Nat Commun (2012) 1.20
Substantia nigra hyperechogenicity is a risk marker of Parkinson's disease: yes. J Neural Transm (Vienna) (2011) 1.19
The origins of oxidant stress in Parkinson's disease and therapeutic strategies. Antioxid Redox Signal (2010) 1.16
The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease. Neurobiol Dis (2011) 1.15
Calcium entry and α-synuclein inclusions elevate dendritic mitochondrial oxidant stress in dopaminergic neurons. J Neurosci (2013) 1.10
Targets for neuroprotection in Parkinson's disease. Biochim Biophys Acta (2008) 1.08
A progressive dopaminergic phenotype associated with neurotoxic conversion of α-synuclein in BAC-transgenic rats. Brain (2013) 1.07
Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics. J Neural Transm (Vienna) (2011) 1.04
The significance of neuronal lateralisation in Parkinson's disease. J Neural Transm (Vienna) (2012) 1.03
The Synaptic Function of α-Synuclein. J Parkinsons Dis (2015) 0.98
Integrative Understanding of Emergent Brain Properties, Quantum Brain Hypotheses, and Connectome Alterations in Dementia are Key Challenges to Conquer Alzheimer's Disease. Front Neurol (2010) 0.96
Agonism of Peroxisome Proliferator Receptor-Gamma may have Therapeutic Potential for Neuroinflammation and Parkinson's Disease. Curr Neuropharmacol (2007) 0.94
Parkinson's disease as a result of aging. Aging Cell (2015) 0.92
WldS but not Nmnat1 protects dopaminergic neurites from MPP+ neurotoxicity. Mol Neurodegener (2012) 0.89
Error processing in patients with Parkinson's disease: the influence of medication state. J Neural Transm (Vienna) (2008) 0.89
Low nigrostriatal reserve for motor parkinsonism in nonhuman primates. Exp Neurol (2012) 0.89
Zebrafish tyrosine hydroxylase 2 gene encodes tryptophan hydroxylase. J Biol Chem (2013) 0.88
Sensorimotor adaptation in Parkinson's disease: evidence for a dopamine dependent remapping disturbance. Exp Brain Res (2007) 0.87
Involvement of insulin-regulated aminopeptidase in the effects of the renin-angiotensin fragment angiotensin IV: a review. Heart Fail Rev (2007) 0.86
Catechol-O-methyltransferase (COMT) Val108/158 Met polymorphism does not modulate executive function in children with ADHD. BMC Med Genet (2004) 0.85
Neuropathobiology of non-motor symptoms in Parkinson disease. J Neural Transm (Vienna) (2015) 0.85
Age-related changes in dopamine signaling in Nurr1 deficient mice as a model of Parkinson's disease. Neurobiol Aging (2011) 0.85
The Parkinsonian mimetic, 6-OHDA, impairs axonal transport in dopaminergic axons. Mol Neurodegener (2014) 0.85
Structure-activity relationship of N,N'-disubstituted pyrimidinetriones as Ca(V)1.3 calcium channel-selective antagonists for Parkinson's disease. J Med Chem (2013) 0.84
Proanthocyanidin-rich fraction from Croton celtidifolius Baill confers neuroprotection in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine rat model of Parkinson's disease. J Neural Transm (Vienna) (2010) 0.84
Oxidative stress defines the neuroprotective or neurotoxic properties of androgens in immortalized female rat dopaminergic neuronal cells. Endocrinology (2013) 0.83
Mice with genetic deletion of the heparin-binding growth factor midkine exhibit early preclinical features of Parkinson's disease. J Neural Transm (Vienna) (2011) 0.82
The progression of idiopathic Parkinson's disease is not explained by age-related changes. Clinical and pathological comparisons with post-encephalitic parkinsonian syndrome. Acta Neuropathol (1987) 0.82
GSK-3β dysregulation contributes to parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synuclein. Cell Death Differ (2014) 0.82
Dysrhythmia of timed movements in Parkinson׳s disease and freezing of gait. Brain Res (2015) 0.81
Neuroprotective effects of cuscutae semen in a mouse model of Parkinson's disease. Evid Based Complement Alternat Med (2014) 0.80
Impact of intravenous immunoglobulin on the dopaminergic system and immune response in the acute MPTP mouse model of Parkinson's disease. J Neuroinflammation (2012) 0.80
Beneficial effects of natural phenolics on levodopa methylation and oxidative neurodegeneration. Brain Res (2012) 0.80
Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson's is associated with histone acetylation and up-regulation of neurotrophic factors. Br J Pharmacol (2015) 0.80
Brain aging phenomena in migrating sockeye salmon Oncorhynchus nerka nerka. J Neural Transm (Vienna) (2005) 0.79
Differential degradation of motor deficits during gradual dopamine depletion with 6-hydroxydopamine in mice. Neuroscience (2015) 0.79
Neuroproteomics as a promising tool in Parkinson's disease research. J Neural Transm (Vienna) (2008) 0.79
Magnetic resonance spectroscopy: an in vivo molecular imaging biomarker for Parkinson's disease? Biomed Res Int (2014) 0.78
Visual dysfunction in patients with Parkinson's disease and essential tremor. Neurol Sci (2014) 0.78
The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015). Mol Psychiatry (2016) 0.77
Absence of glia maturation factor protects dopaminergic neurons and improves motor behavior in mouse model of parkinsonism. Neurochem Res (2015) 0.76
Transplantation into the human brain: present status and future possibilities. J Neurol Neurosurg Psychiatry (1989) 0.76
Executive functioning in TBI from rehabilitation to social reintegration: COMPASS (goal,) a randomized controlled trial (grant: 1I01RX000637-01A3 by the VA ORD RR&D, 2013-2016). Mil Med Res (2015) 0.76
Executive function deficits and glutamatergic protein alterations in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. J Neurosci Res (2015) 0.75
Identification of Multiple QTLs Linked to Neuropathology in the Engrailed-1 Heterozygous Mouse Model of Parkinson's Disease. Sci Rep (2016) 0.75
Involvement of the sodium-calcium exchanger 3 (NCX3) in ziram-induced calcium dysregulation and toxicity. Neurotoxicology (2014) 0.75
Early Degeneration of Both Dopaminergic and Serotonergic Axons - A Common Mechanism in Parkinson's Disease. Front Cell Neurosci (2016) 0.75
Conditional deletion of Ndufs4 in dopaminergic neurons promotes Parkinson's disease-like non-motor symptoms without loss of dopamine neurons. Sci Rep (2017) 0.75
Neuroprotective Effects of Salidroside in the MPTP Mouse Model of Parkinson's Disease: Involvement of the PI3K/Akt/GSK3β Pathway. Parkinsons Dis (2016) 0.75
Brain monoamines in human cerebral infarcts. A preliminary study. Acta Neuropathol (1978) 0.75
Magnetic resonance imaging markers for early diagnosis of Parkinson's disease. Neural Regen Res (2012) 0.75
Cell-specific pallidal intervention induces long-lasting motor recovery in dopamine-depleted mice. Nat Neurosci (2017) 0.75
The pharmacodynamic characterization of an antisense oligonucleotide against monoamine oxidase-B (MAO-B) in rat brain striatal tissue. Cell Mol Neurobiol (2001) 0.75
Allelic variation of human serotonin transporter gene expression. J Neurochem (1996) 7.08
AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry (2011) 2.91
Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett (1994) 2.27
Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett (1995) 2.19
Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett (1994) 2.17
Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm (1988) 2.10
CNTF and endogenous psychoses? Nat Genet (1996) 2.02
Organization of the human serotonin transporter gene. J Neural Transm Gen Sect (1994) 1.97
Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm (Vienna) (1998) 1.90
Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm (Vienna) (2004) 1.89
Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J Neural Transm (1985) 1.89
Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued. Eur J Clin Pharmacol (1992) 1.86
Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol (2001) 1.81
Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem (1991) 1.70
The 5-HT transporter gene-linked polymorphic region (5-HTTLPR) in evolutionary perspective: alternative biallelic variation in rhesus monkeys. Rapid communication. J Neural Transm (Vienna) (1997) 1.65
The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry (2004) 1.64
The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. J Neural Transm (1975) 1.62
Human brain dopamine receptors in children and aging adults. Synapse (1987) 1.55
Brain iron pathways and their relevance to Parkinson's disease. J Neurochem (2001) 1.55
Borna disease virus in human brains with a rare form of hippocampal degeneration but not in brains of patients with common neuropsychiatric disorders. J Infect Dis (1999) 1.53
Cell death and apoptosis regulating proteins in Parkinson's disease--a cautionary note. Acta Neuropathol (1999) 1.48
Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem (1994) 1.46
Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm (Vienna) (1996) 1.45
Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett (1992) 1.44
N-methyl-(R)-salsolinol and its relevance to Parkinson's disease. Lancet (1998) 1.40
Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study. Lancet (1977) 1.38
Progressive supranuclear palsy: clinico-pathological and biochemical studies. J Neural Transm Suppl (1980) 1.38
Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr Res (2001) 1.37
Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease. Prog Neurobiol (2005) 1.37
Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's disease. J Alzheimers Dis (2007) 1.36
Alzheimer's disease--synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm (Vienna) (1998) 1.35
Oxidative stress: free radical production in neural degeneration. Pharmacol Ther (1994) 1.33
Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J Neurochem (2001) 1.33
Bimodal distribution of dopamine receptor densities in brains of schizophrenics. Science (1984) 1.28
Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J Neural Transm Park Dis Dement Sect (1990) 1.27
High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J Neural Transm (Vienna) (2004) 1.26
Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder. Neurotox Res (2006) 1.26
Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol (1991) 1.26
Serotonin, noradrenaline, dopamine metabolites in transcendental meditation-technique. J Neural Transm (1976) 1.26
Impaired phosphorylation of cyclic AMP response element binding protein in the hippocampus of dementia of the Alzheimer type. Brain Res (1999) 1.24
Functional promoter and polyadenylation site mapping of the human serotonin (5-HT) transporter gene. J Neural Transm Gen Sect (1995) 1.23
Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem (1997) 1.21
Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology (1987) 1.20
Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J Neural Transm (Vienna) (2003) 1.18
Giant ovarian leiomyoma as a rare cause of acute abdomen and hydronephrosis. Obstet Gynecol (1996) 1.17
The possible role of iron in the etiopathology of Parkinson's disease. Mov Disord (1993) 1.15
MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol (1991) 1.13
Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl (1994) 1.11
Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. Neurosci Lett (1994) 1.10
Influence of neurotoxins and oxidative stress on the onset and progression of Parkinson's disease. J Neurol (2000) 1.10
Neuronal and glial coexpression of argininosuccinate synthetase and inducible nitric oxide synthase in Alzheimer disease. J Neuropathol Exp Neurol (2001) 1.10
Human post-mortem striatal alpha4beta2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome. Neurosci Lett (2000) 1.10
Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour. Mol Pathol (2001) 1.09
Insulin-degrading enzyme in the Alzheimer's disease brain: prominent localization in neurons and senile plaques. Neurosci Lett (1999) 1.08
How a neuropsychiatric brain bank should be run: a consensus paper of Brainnet Europe II. J Neural Transm (Vienna) (2006) 1.07
Diagnostic staging of Parkinson's disease: conceptual aspects. J Neural Transm (Vienna) (2004) 1.06
Age-dependent memory loss, synaptic pathology and altered brain plasticity in the Drosophila mutant cardinal accumulating 3-hydroxykynurenine. J Neural Transm (Vienna) (2000) 1.06
Cytotoxicity of advanced glycation endproducts is mediated by oxidative stress. J Neural Transm (Vienna) (1998) 1.06
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Brain Res (1996) 1.06
Parkinson's disease and depression: evidence for an alteration of the basal limbic system detected by transcranial sonography. J Neurol Neurosurg Psychiatry (1997) 1.05
Allelic variation of serotonin transporter expression is associated with depression in Parkinson's disease. Mol Psychiatry (2001) 1.05
On the mode of action of L-deprenyl in the human central nervous system. J Neural Transm (1978) 1.05
Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis. J Neurochem (1992) 1.04
Pulmonary meningioma. Immunohistochemical and ultrastructural features. Am J Surg Pathol (1991) 1.04
Primary structure of the serotonin transporter in unipolar depression and bipolar disorder. Biol Psychiatry (1995) 1.04
Isolation of a cDNA encoding the human brain serotonin transporter. J Neural Transm Gen Sect (1993) 1.03
Potential sources of increased iron in the substantia nigra of parkinsonian patients. J Neural Transm Suppl (2006) 1.03
High molecular weight hyaluronic acid inhibits advanced glycation endproduct-induced NF-kappaB activation and cytokine expression. FEBS Lett (1999) 1.03
Distinction between benign and malignant type of Parkinson's disease. Clin Neurol Neurosurg (1979) 1.03
Dementia in Parkinson's disease and (pre) senile dementia of Alzheimer type: morphological aspects and changes in the intracerebral MAO activity. Adv Neurol (1984) 1.03
A disturbance in the neuronal insulin receptor signal transduction in sporadic Alzheimer's disease. Ann N Y Acad Sci (1999) 1.03
Advanced glycation endproducts in ageing and Alzheimer's disease. Brain Res Brain Res Rev (1997) 1.02
Iron in brain function and dysfunction with emphasis on Parkinson's disease. Eur Neurol (1991) 1.02
Parkinsonism in HIV dementia. J Neural Transm (Vienna) (2002) 1.02
Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol (1989) 1.01
Microglia activation is related to substantia nigra echogenicity. J Neural Transm (Vienna) (2010) 1.01
AGES in brain ageing: AGE-inhibitors as neuroprotective and anti-dementia drugs? Biogerontology (2001) 1.01
Enhancement of central nervous system pathology in early simian immunodeficiency virus infection by dopaminergic drugs. Acta Neuropathol (2001) 1.00
Crosslinking of alpha-synuclein by advanced glycation endproducts--an early pathophysiological step in Lewy body formation? J Chem Neuroanat (2000) 1.00
Far field potentials from the brain stem after transcutaneous vagus nerve stimulation. J Neural Transm (Vienna) (2003) 1.00
Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? Acta Neurol Scand Suppl (1989) 0.99
Potential genetic markers of sporadic Alzheimer's dementia. Psychiatr Genet (2001) 0.99
Iron accumulation in the substantia nigra in rats visualized by ultrasound. Ultrasound Med Biol (1999) 0.99
Brain-derived neurotrophic factor and neurotrophin-3 levels in Alzheimer's disease brains. Int J Dev Neurosci (2000) 0.99
Reduced phosphorylation of cyclic AMP-responsive element binding protein in the postmortem orbitofrontal cortex of patients with major depressive disorder. J Neural Transm (Vienna) (2003) 0.99
Glutamate receptor antagonists for neuroleptic malignant syndrome and akinetic hyperthermic parkinsonian crisis. J Neural Transm Park Dis Dement Sect (1993) 0.98
Involvement of dopamine in the progression of AIDS Dementia Complex. J Neural Transm (Vienna) (2002) 0.98
Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. J Neurochem (1986) 0.98
Brain monoamines in human hepatic encephalopathy. Acta Neuropathol (1978) 0.98
Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J Neurochem (1991) 0.98
Persistence of haloperidol in human brain tissue. Am J Psychiatry (1999) 0.98
The effect of simian immunodeficiency virus infection in vitro and in vivo on the cytokine production of isolated microglia and peripheral macrophages from rhesus monkey. Virology (1996) 0.97
Understanding Parkinson's disease. Sci Am (1997) 0.96
Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice. Neuroreport (1995) 0.95
A promoter-associated polymorphic repeat modulates PAX-6 expression in human brain. Biochem Biophys Res Commun (1998) 0.95
Quantification of mRNA of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in the substantia nigra in Parkinson's disease and schizophrenia. J Neural Transm Park Dis Dement Sect (1994) 0.95
Abnormal localization of two neuronal calcium sensor proteins, visinin-like proteins (vilips)-1 and -3, in neocortical brain areas of Alzheimer disease patients. Dement Geriatr Cogn Disord (2001) 0.94
Alpha-lipoic acid as a new treatment option for Alzheimer [corrected] type dementia. Arch Gerontol Geriatr (2001) 0.94